CoChat
Sign Up
Cited by 142

The DOI matches its Crossref record.

HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells

Campo, M.S., Graham, S.V., Cortese, M.S., Ashrafi, G.H., Araibi, E.H., Dornan, E.S., Miners, K., Nunes, C., Man, S.·2010·Virology
DOI 10.1016/j.virol.2010.07.044
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.virol.2010.07.044

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 28

  1. Aasen, 2003, The relationship between connexins, gap junctions, tissue architecture and tumour invasion, as studied in a novel in vitro model of HPV-16-associated cervical cancer progression, Oncogene, 22, 7969, 10.1038/sj.onc.1206709 · DOI
  2. Alazawi, 2002, Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16, Cancer Res., 62, 6959
  3. Araibi, E.H. (2006). Down-regulation of MHC class I by papillomavirus E5 proteins. PhD Thesis, University of Glasgow.
  4. Araibi, 2004, Down-regulation of MHC class I in bovine papillomas, J. Gen. Virol., 85, 2809, 10.1099/vir.0.80128-0 · DOI
  5. Araibi, 2006, The E5 oncoprotein of BPV-4 does not interfere with the biosynthetic pathway of non-classical MHC class I, Virology, 353, 174, 10.1016/j.virol.2006.05.031 · DOI
  6. Ashrafi, 2002, Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins, Oncogene, 21, 248, 10.1038/sj.onc.1205008 · DOI
  7. Ashrafi, 2005, The E5 protein of human papillomavirus type 16 selectively down-regulates surface HLA class, Int. J. Cancer, 113, 276, 10.1002/ijc.20558 · DOI · Paper page
  8. Ashrafi, 2006, E5 protein of human papillomavirus 16 down-regulates HLA class I and interacts with the heavy chain via its first hydrophobic domain, Int. J. Cancer, 119, 2105, 10.1002/ijc.22089 · DOI · Paper page
  9. Cortese, 2010, All four di-leucine motifs in the first hydrophobic domain of the E5 oncoprotein of human papillomavirus type 16 are essential for surface MHC class I down-regulation activity and E5 endomembrane localisation, Int. J. Cancer, 126, 1675, 10.1002/ijc.25004 · DOI · Paper page
  10. Ellis, 1999, Variation in the number of expressed MHC genes in different cattle class I haplotypes, Immunogenetics, 50, 319, 10.1007/s002510050608 · DOI
  11. Evans, 2001, Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6, J. Immunol., 167, 5420, 10.4049/jimmunol.167.9.5420 · DOI
  12. Jeon, 1995, Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells, J. Virol., 69, 2989, 10.1128/jvi.69.5.2989-2997.1995 · DOI
  13. Kenter, 2009, Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia, N Engl J. Med., 361, 1838, 10.1056/NEJMoa0810097 · DOI
  14. Knowles, 1996, Phenotypical characterization of lymphocytes infiltrating regressing papillomas, J. Virol., 70, 8451, 10.1128/jvi.70.12.8451-8458.1996 · DOI
  15. Lilley, 2005, Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond, Immunol. Rev., 207, 126, 10.1111/j.0105-2896.2005.00318.x · DOI
  16. Marchetti, 2002, The papillomavirus oncoprotein E5 retains the major histocompatibility class I in the Golgi apparatus and prevents its transport to the cell surface, Oncogene, 21, 7808, 10.1038/sj.onc.1205885 · DOI
  17. Marchetti, 2009, Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain, J. Gen. Virol., 90, 2865, 10.1099/vir.0.014746-0 · DOI
  18. McPhillips, 2004, SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells, J. Virol., 78, 10598, 10.1128/JVI.78.19.10598-10605.2004 · DOI
  19. Nicholls, 2001, Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes, Virology, 283, 31, 10.1006/viro.2000.0789 · DOI
  20. O'Brien, 2002, Evasion of host immunity directed by papillomavirus-encoded proteins, Virus Res., 1–2, 103, 10.1016/S0168-1702(02)00123-5 · DOI
  21. Schapiro, 2000, Golgi alkalinization by the papillomavirus E5 oncoprotein, J. Cell Biol., 148, 305, 10.1083/jcb.148.2.305 · DOI
  22. Selvakumar, 1997, Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression, J. Virol., 71, 5540, 10.1128/jvi.71.7.5540-5548.1997 · DOI
  23. Stanley, 2007, HPV: from infection to cancer, Biochem. Soc. Trans., 035, 1456, 10.1042/BST0351456 · DOI
  24. Thomas, 2008, HPV16 E629-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function, Int. J. Cancer, 122, 2791, 10.1002/ijc.23475 · DOI
  25. Tomasec, 2000, Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40, Science, 287, 1031, 10.1126/science.287.5455.1031 · DOI
  26. Valitutti, 1996, Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy, J. Exp. Med., 183, 1917, 10.1084/jem.183.4.1917 · DOI
  27. Youde, 2005, Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line, Int. J. Cancer, 114, 606, 10.1002/ijc.20779 · DOI
  28. zur Hausen, 2009, Papillomaviruses in the causation of human cancers—a brief historical account, Virology, 384, 260, 10.1016/j.virol.2008.11.046 · DOI · Paper page

Cited by

Metadata

Authors
Campo, M. S., Graham, S. V., Cortese, M. S., Ashrafi, G. H., Araibi, E. H., Dornan, E. S., Miners, K., Nunes, C., & Man, S.
Venue
Virology
Publisher
Elsevier BV
Published
2010-11
Volume
407
Issue
1
Pages
137-142
ISSN
0042-6822
DOI
10.1016/j.virol.2010.07.044
Cited by
142
References
0
Language
en
Licence
Funders
  • Cancer Research UK
  • Association for International Cancer Research
  • Cancer Research Wales
  • Ministry of Education, Libya

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review